This company has been marked as potentially delisted and may not be actively trading. Alterity Therapeutics (PRAN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock PRAN vs. BIOA, NLTX, CYBN, VIRI, WHWK, OSTX, ELYM, ATNM, NBRV, and AADIShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include BioAge Labs (BIOA), Neoleukin Therapeutics (NLTX), Cybin (CYBN), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), and Aadi Bioscience (AADI). Alterity Therapeutics vs. Its Competitors BioAge Labs Neoleukin Therapeutics Cybin Virios Therapeutics Whitehawk Therapeutics OS Therapies Eliem Therapeutics Actinium Pharmaceuticals Nabriva Therapeutics Aadi Bioscience Alterity Therapeutics (NASDAQ:PRAN) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk. Which has better valuation and earnings, PRAN or BIOA? Alterity Therapeutics has higher earnings, but lower revenue than BioAge Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity Therapeutics$150K289.55-$6.40M-$0.70-6.97BioAge Labs$3.86M44.92-$71.11MN/AN/A Do insiders and institutionals hold more shares of PRAN or BIOA? 3.6% of Alterity Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 20.8% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor PRAN or BIOA? In the previous week, BioAge Labs had 2 more articles in the media than Alterity Therapeutics. MarketBeat recorded 2 mentions for BioAge Labs and 0 mentions for Alterity Therapeutics. BioAge Labs' average media sentiment score of 0.95 beat Alterity Therapeutics' score of 0.00 indicating that BioAge Labs is being referred to more favorably in the news media. Company Overall Sentiment Alterity Therapeutics Neutral BioAge Labs Positive Is PRAN or BIOA more profitable? Alterity Therapeutics' return on equity of 0.00% beat BioAge Labs' return on equity.Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A BioAge Labs N/A -25.39%-23.22% SummaryAlterity Therapeutics beats BioAge Labs on 6 of the 9 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAN vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.43M$860.33M$5.75B$10.27BDividend YieldN/A4.84%5.73%4.60%P/E Ratio-6.971.1775.1826.37Price / Sales289.55119.80457.0688.69Price / CashN/A19.5625.8129.91Price / Book3.496.6613.256.28Net Income-$6.40M-$4.13M$3.29B$270.67M Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRANAlterity TherapeuticsN/A$4.88-1.2%N/A+287.3%$43.43M$150K-6.9714BIOABioAge Labs0.2017 of 5 stars$4.65-5.7%N/AN/A$176.74MN/A0.00N/AHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$18.48-1.9%N/A-54.7%$173.68MN/A-5.9490CYBNCybin2.687 of 5 stars$6.24-16.6%$85.00+1,262.2%N/A$147.20MN/A-1.4250High Trading VolumeVIRIVirios TherapeuticsN/A$4.96+3.4%$5.00+0.8%+2,409.0%$95.52MN/A-18.375WHWKWhitehawk Therapeutics1.1848 of 5 stars$1.82+0.8%N/AN/A$85.07M$25.98M-30.3340OSTXOS Therapies2.0696 of 5 stars$2.23-6.7%$18.00+707.2%-34.6%$70.57MN/A-2.82N/AAnalyst ForecastELYMEliem TherapeuticsN/A$2.23-3.0%N/A-73.4%$66.35MN/A-4.219News CoverageATNMActinium Pharmaceuticals2.2138 of 5 stars$1.73-2.8%$4.50+160.1%-12.4%$53.97MN/A-1.2430Positive NewsNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070AADIAadi BioscienceN/A$1.81+2.0%N/A+10.6%$44.58M$25.07M-0.7940Gap Down Related Companies and Tools Related Companies BioAge Labs Competitors Neoleukin Therapeutics Competitors Cybin Competitors Virios Therapeutics Competitors Whitehawk Therapeutics Competitors OS Therapies Competitors Eliem Therapeutics Competitors Actinium Pharmaceuticals Competitors Nabriva Therapeutics Competitors Aadi Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAN) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
